Carvedilol can Prevent Cardiac Events in Duchenne Muscular Dystrophy
スポンサーリンク
概要
- 論文の詳細を見る
Objective Heart failure is one of the most serious complications in Duchenne muscular dystrophy (DMD). Beta-blocker medication is known to improve the prognosis of chronic heart failure of adults, but its efficacy and safety for DMD patients has not been fully assessed. Thus we conducted a multicenter open trial. Methods Fifty-four DMD patients participated; 41 received carvedilol (BB group) and 13 did not (non BB group). All patients with an ejection fraction of less than 50% received angiotensin-converting enzyme inhibitor. Then, patients in BB group were started on carvedilol. The mean maintenance dose of carvedilol in BB group was 7.85±2.80 mg/day. Clinical signs and cardiac function were monitored regularly and statistical analysis was done. Results The survival rate free from primary endpoints (death, deterioration of heart failure and severe arrhythmia) was higher in the BB group. The survival rate free from all-cause death was also higher in the BB group, although not significantly higher. Patients with primary endpoints received lower maintenance doses of carvedilol and presented higher mean heart rates (HR) during the observation period. In the BB group, mean HR at enrollment and the reduction of mean HR were correlated with the change of ejection fraction. Although serious adverse events were rare during the introduction of carvedilol, patients with advanced cardiac dysfunction required a longer period for up-titration and frequently presented with minor complaints. Conclusion The present study suggests that carvedilol is relatively safe and can prevent cardiac events even in patients with DMD.
著者
-
Matsumura Tsuyoshi
Department of Neurology, National Hospital Organization Toneyama National Hospital
-
Tamura Takuhisa
Department of Internal Medicine, National Hospital Organization Higashi-Saitama National Hospital
-
Kuru Satoshi
Department of Neurology, National Hospital Organization Suzuka National Hospital
-
Kikuchi Yasuki
Department of Occupational Therapy, Nagasaki University School of Health Science
-
Kawai Mitsuru
Department of Neurology, National Hospital Organization Higashi-Saitama National Hospital
-
Kuru Satoshi
Department Of Neurology Suzuka National Hospital
-
Tamura Takuhisa
Department Of Internal Medicine National Sanatorium Kawatana Hospital
-
Kawai Mitsuru
Department of Neurology, Higashi-Saitama National Hospital
関連論文
- Carvedilol can Prevent Cardiac Events in Duchenne Muscular Dystrophy
- Mental Retardation and Lifetime Events of Duchenne Muscular Dystrophy in Japan
- An autopsy case of spinal muscular atrophy type III (Kugelberg-Welander disease)
- Dilated Cardiomyopathy in Kugelberg-Welander Disease : Coexisting Sleep Disordered Breathing and Its Treatment with Continuous Positive Airway Pressure
- Assessment of Cardiomyopathy in Patients with Duchenne Muscular Dystrophy by Myocardial SPECT Usi_ng ^TICI and ^I-BMIPP
- Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients
- Intravesical mass consisting of mucosa-associated lymphoid tissue
- Autopsy case of hereditary spastic paraplegia with thin corpus callosum showing severe gliosis in the cerebral white matter
- Molecular genetic analysis of dysferlin in Japanese patients with Miyoshi myopathy
- A Novel SACS Mutation in an Atypical Case with Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)
- Lung Inflation Training Using a Positive End-expiratory Pressure Valve in Neuromuscular Disorders
- Decreased resting energy expenditure in patients with Duchenne muscular dystrophy
- Evaluation of Myocardial Damage in Duchenne's Muscular Dystrophy with Thallium-201 Myocardial SPECT.
- Heart Rate Variability and Hypercapnia in Duchenne Muscular Dystrophy